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Abstract
Background: FTY720 (Fingolimod) is a novel immunosuppressive drug investigated in clinical trials for organ
transplantation and multiple sclerosis. It acts as a functional sphingosine-1-phosphate (S1P) receptor antagonist,
thereby inhibiting the egress of lymphocytes from secondary lymphoid organs. As S1P is able to prevent IL-1beta
induced cartilage degradation, we examined the direct impact of FTY720 on cytokine induced cartilage destruction.
Methods: Bovine chondrocytes were treated with the bioactive phosphorylated form of FTY720 (FTY720-P) in
combination with IL-1beta or TNF-alpha. Expression of MMP-1,-3.-13, iNOS and ADAMTS-4,-5 and COX-2 was
evaluated using quantitative real-time PCR and western blot. Glycosaminoglycan depletion from cartilage explants
was determined using a 1,9-dimethylene blue assay and safranin O staining.
Results: FTY720-P significantly reduced IL-1beta and TNF-alpha induced expression of iNOS. In contrast FTY720-P
increased MMP-3 and ADAMTS-5 mRNA expression. Furthermore depletion of glycosaminoglycan from cartilage
explants by IL-1beta and TNF-alpha was significantly enhanced by FTY720-P in an MMP-3 dependent manner.
Conclusions: Our results suggest that FTY720 may enhance cartilage degradation in pro-inflammatory
environment.
Keywords: chondrocyte, fingolimod, FTY720, interleukin-1β, tumor necrosis factor-α, inducible nitric oxide synthase,
glycosaminoglycan
Background
Since the introduction of the anti-TNF antibody as a ther-
apy for rheumatoid arthritis (RA) in the late 1990’st h e
armamentarium of protein-based immune-modulating
drugs has steadily increased. In the next decade rheuma-
tologists will be able to apply a novel class of therapeutic
tools. The new group of small-molecule drugs are specific
inhibitors of inter- or intra-cellular signalling pathways.
They are orally active and can be produced at low cost.
However, the target molecules of these drugs may be
expressed in other organ systems as well. This may result
in unforeseeable adverse events upon long-time treatment.
FTY720 (fingolimod) is such a novel small-molecule
immunosuppressant. Its immunosuppressive efficacy has
been documented in large-scale prospective phase III
studies in renal transplantation [1] and multiple sclerosis
[2,3]. Oral intake of FTY720 leads to marked reduction
of the number of circulating T- and B lymphocytes [1].
Unlike other immunosuppressants it does not impair
lymphocyte proliferation, nor does it induce apoptosis of
lymphocytes [4].
Due to its structural analogy with the naturally occur-
ring lipid sphingosine most cells take up FTY720 to
phosphorylate it to its bioactive form FTY720-P [5]. In
lymphocytes FTY720-P interacts with the receptors for
Sphingosine-1-phosphate (S1P), thereby internalizing the
S1P receptor-subtype 1 (S1P1) [6]. Since the S1P1 recep-
tor is necessary to egress the lymph nodes, its neutraliza-
tion inhibits the migration of lymphocytes into the
circulation leading to the immunosuppressive activity of
this substance [7].
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have not been registered so far, its use in RA has been
proposed [8]. In rat collagen-induced arthritis FTY720
inhibited the formation of synovitis and bone erosions
more effectively than prednisone [9]. In the adjuvant-
induced arthritis rat model FTY720 inhibited joint
inflammation as successful as tacrolimus and cyclos-
porin A [10].
Moreover, FTY720 may also impair S1P signaling in
other cell types. For chondrocytes S1P is protective by
limiting glycosaminoglycan (GAG) degradation and indu-
cing proliferation [11,12]; moreover it stimulates prosta-
glandin E2 release via S1P receptor subtypes S1P1-3 [13].
Direct effects of FTY720 on articular cartilage have not
been reported so far. Since FTY720 leads to a perturba-
tion of S1P signaling, its use as an immunosuppressant
could have an impact on articular cartilage.
This study therefore aims to evaluate the in vitro
impact of FTY720 on chondrocytes in the presence of
pro-inflammatory cytokines in analogy to the situation
found within rheumatoid arthritis joints. As risk indica-
tors for cartilage damage we used iNOS expression and
release of GAG.
Methods
Reagents
FTY720-P was kindly donated by Novartis Pharma AG
(Basel, Switzerland) and dissolved in DMSO-HCL.
Bovine IL-1b and TNF-a were purchased from AbD Ser-
otec(Oxford, UK). XG076 was purchased at Calbiochem
(Darmstadt, Germany). DMEM High Glucose with
L-Glutamine, DMEM/Ham’s F-12 with L-Glutamine 1:1,
FCS and Penicillin/Streptomycin solution was purchased
at PAA Laboratories (Pasching, Austria). We acquired
iNOS antibodies (Upstate, Lake Placid, NY) and antibo-
dies for actin (Sigma-Aldrich, St. Louis, MO). Secondary
antibody was purchased from Cell Signaling (Danvers,
MA).
Cell culture
Cartilage was harvested from bovine metacarpophalan-
geal joints of adult cows (20 - 24 months, n = 21) under
a s e p t i cc o n d i t i o n s .C a r t i l a g et i s s u ew a sm i n c e da n d
digested in 0.2% collagenase B (F. Hoffman La Roche
Ltd., Basel, Switzerland) for 16 hours. The resulting cell
suspension was filtered through a nylon mesh with pores
of 70 μm (BD Pharma, Le Pont-De-Claix, France). Cells
were counted and viability tested using trypan blue dye
(Sigma-Aldrich). Bovine chondrocytes were then cultured
in monolayer at 37°C, 5% O2 and 5% CO2, in DMEM/F-
12 1:1 supplemented with 10% FCS and 1% Penicillin/
Streptomycin solution over 1 passage. Upon 80%-90%
confluence cultures were incubated with serum free med-
ium 24 h prior to experiments. Chondrocyte viability in
the presence of 0.01 μMt o1 0μM FTY720-P, the corre-
sponding amount of vehicle (DMSO-HCL) and 100 μM
XG076 was assessed for 72 h using a MTS ([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay (Promega, Madison,
WI) according to the manufacturers protocol. MTS assay
was carried out in hexaplicates and repeated three times
using chondrocytes from 3 different animals
Real-time PCR
Three independent experiments using chondrocytes
from 3 different animals were performed in duplicates
for each treatment group. Chondrocytes were allowed to
grow over one passage and upon 80%-90% confluence
cultures were serum-depleted 24 h prior to experiments.
Chondrocytes were then treated with 10 ng/ml IL-1b or
100 ng/ml TNF-a in combination with 0.1 to 3 μM
FTY720-P or vehicle solution for 3 h. RNA was isolated
using Tri-reagent (Sigma-Aldrich, St. Louis, MO)
according to the manufacturers recommended protocol.
To avoid potential DNA contamination, DNA was
digested with 1 U DNase (Fermentas, Burlington, ON)
per μg RNA for 30 minutes at 37°C. A total of 1 μgo f
RNA was then reverse transcribed using RevertAid
cDNA Synthesis Kit (Fermentas) and random hexamer
primers according to the provided manual. For amplifi-
cation all samples were run in triplicates using a master
mix containing SYBR green (2× SYBR Green PCR Mas-
ter Mix, Invitrogen Corp., Carlsbad, CA). Primers
(MWG, Ebersberg, Germany) were designed with
Primer3 software [14]. Sequences of primers are listed
in additional file 1, Table S1. For normalization the
housekeeping genes Hydroxymethyl-bilane synthase,
Beta-2-microglobulin, Beta actin, Hypoxanthine phos-
phoribosyltransferase 1, Ribosomal protein S18 and
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were evaluated in our experimental setting. GAPDH
showed the least variation over all treatments and was
therefore chosen as housekeeping gene for the following
analyses. The relative amount of cDNA was calculated
using ABI prism sequence detecting software (Applied
Biosystems) based on a standard curve, according to the
manufacturers’ manual. Minimum information for publi-
cation of quantitative real-time PCR experiments is sup-
plied in additional files 1 and 2[15].
Western blot analysis
Three independent experiments using chondrocytes from
3 different animals were performed. Chondrocytes were
allowed to grow over one passage and upon 80%-90%
confluence cultures were serum-depleted 24 h prior to
experiments. Total protein was extracted from cultured
chondrocytes after 24 h of treatment with10 ng/ml IL-1b
in combination with 3 μM FTY720-P or vehicle solution,
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Triton X-100, 5 mM EDTA, 1% protease inhibitor cock-
tail; all Sigma Aldrich). After brief sonication protein
concentration was measured with DC Protein assay
(BioRad). 7 μg of protein were separated by SDS-PAGE
using a 10% polyacrylamide gel and were transferred to a
nitrocellulose membrane (Bi o R a d ,H e r c u l e s ,C A ) .A f t e r
overnight blocking in 5% skim milk in Tris-buffered sal-
ine the membranes were incubated with primary antibo-
dies against iNOS (1:2000) and actin (1:5000) for 2 h.
Thereafter membranes were rinsed in blocking solution
and incubated for 1 h with secondary antibody conju-
gated to horseradish peroxidase (1:3000). Bands were
visualized using ECL plus detection system (Amersham,
Arlington Heights, IL).
Determination of Glycosaminoglycan (GAG) release
Three independent experiments were performed using
cartilage from 3 different animals. Cartilage explants of 4
× 4 × 2 mm (wet weight 13,3 mg ± 0.9 mg) were har-
vested from bovine metacarpophalangeal joints under
aseptic conditions and cultured at 37°C, 5% O2 and 5%
CO2, in DMEM/F-12 1:1 supplemented with 10% FCS
and 1% Penicillin/Streptomycin solution for 24 h. After
another 24 h in the absence of FCS cartilage explants
were treated with 0.5-3 μM FTY720-P or vehicle control
and 10 ng/ml IL-1b or 100 ng/ml TNF-a over 5 days.
Medium was changed and treatment renewed on day 3.
Treatment was carried out in triplicates for each treat-
ment group. Thereafter explants were weighted and
digested in phosphate buffer (2.76 g/l NaH2PO4, 0.38 g/l
EDTA, 0.25 g/l DTT all Sigma-Aldrich, pH 6.8) contain-
ing 0.6 g/l papain (Sigma-Aldrich). GAG concentration
in culture supernatants of day 3, day 5 and the digested
explants was determined by 1,9-dimethylene blue (DMB;
Sigma-Aldrich) reaction [11,16]. In brief 20 μlo ft h e
samples and chondroitin sulphate (Sigma-Aldrich) stan-
dard dilution were incubated with 180 μlD M Bs o l u t i o n
(38.5 μM DMB, 40 mM NaCl, 40 mM glycin, 0.5% Etha-
nol, pH 3) for 5 minutes. Absorbance at 530 nm was
measured with Spectra max 384-plate reader. Results
were normalized to wet weight of the explants.
Histological examination
Three independent experiments using cartilage from 3
different animals were performed. Bovine cartilage
explants were harvested as described above and were cul-
tured at 37°C, 5% O2 and 5% CO2, in DMEM/F-12 1:1
supplemented with 1%Penicilin/Streptomycin solution.
Media containing either 10 ng/ml IL-1b or 100 ng/ml
TNF-a in combination with 3 μM FTY720-P or vehicle
solution was changed on the 3
rd and 6
th day. Upon 8
days of treatment, cartilage explants were fixed in 4% for-
malin solution for 24 hours and then embedded in
paraffin. Sections of 3 μm were stained with 0.1% safranin
O solution, 0.001% fast green solution and Weigert’s iron
hematoxylin solution [17].
Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM). Real-time RT-PCR results are expressed as
mean ± SEM percentage over control. Normal distribu-
tion of the data was assessed using Kolmogorov-Smirnov
test. Data in all treatment groups were normally distribu-
ted. Data were analyzed by one-way ANOVA followed by
post-hoc analysis using Bonferroni corrected t-test. SPSS
13.0 (IBM, Chicago, IL) was used for statistical analysis.
Differences between two groups were considered signifi-
cant at the P < 0.05 level.
Results
FTY720-P reduces cytokine induced iNOS expression
Chondrocyte viability was unchanged in the presence of
up to 10 μM FTY720-P or 100 μM of the MMP-3 inhi-
bitor XG076 (P > 0.05, data not shown). Treatment of
chondrocytes with 10 ng/ml interleukin-1 (IL-1)b
resulted in 18-fold up-regulation of iNOS mRNA
expression (P < 0.05). Co-treatment with up to 3 μM
FTY720-P reduced iNOS mRNA expression by 40 ± 8%
(mean ± SEM, P < 0.05) compared to vehicle solution.
(Figure 1A)
Treatment with 100 ng/ml tumor necrosis factor
(TNF)-a l e dt oa1 8 - f o l d( P < 0.05) up-regulation of
iNOS mRNA. Co-treatment with 3 μM of FTY720-P
reduced TNF-a induced iNOS expression by 47 ± 16%
(P < 0.05). A similar trend was observed when IL-1b sti-
mulated chondrocytes were co-treated with unpho-
sphorylated FTY720 (data not shown). The maximal
effect was observed later (after 6 h) and was less pro-
nounced compared to treatment with FTY720-P.
iNOS protein expression was significantly enhanced
after 24 h of treatment with IL-1b (24-fold, P <0 . 0 1 )o r
TNF-a (11-fold, P <0 . 0 1 ) .A se x p e c t e df r o mR T - P C R
results, co-treatment with 3 μM of FTY720-P reduced
IL-1b and TNF-a induced iNOS protein expression by
39%, (P < 0.05) and 69.4% (P < 0.05) respectively (Figure
1B and 1C).
FTY720-P enhances cytokine induced glucosaminoglycan
(GAG) depletion
Culturing cartilage explants for 8 days with 0.1-3 μMo f
FTY720-P did not result in altered depletion of GAG
compared to vehicle treated cartilage (Figure 2G). IL-1b
induced a significant increase in GAG depletion (Figure
2H). Untreated cartilage explants lost 5.9 ± 1.3 μg
GAG/mg wet weight over 5 days compared to 23.7 ±
3.9 μg/mg lost by IL-1b treated explants (P <0 . 0 5 ) .
Furthermore co-treatment with FTY720-P resulted in
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of IL-1b with 3 μM of FTY720 increased GAG depletion
to 38.4 ± 4.3 μg/mg (P <0 . 0 5c o m p a r e dt oI L - 1t r e a t -
ment). Treating cartilage explants with TNF-a led to a
GAG depletion of 12.3 ± 1.0 μg/mg, which was not sig-
nificantly different from untreated explants (7.5 ± 2.1
μg/mg, P = 0.18). Upon incubation with FTY720-P a
significant increase in GAG depletion was observed.
3 μM of FTY720-P led to 31.2 ± 6.2 μg/mg (P < 0.01 vs.
TNF-a) of GAG depleted from cartilage explants (Figure
2H).
These results were confirmed by histology in an inde-
pendent series of experiments. GAG content as deter-
mined by safraninO staining in FTY720-P treated cartilage
was not different from untreated cartilage (Figure 2A and
2B). IL-1b treatment resulted in considerable discoloration
of cartilage. Co-treatment with 3 μM of FTY720-P further
enhanced the effect (Figure 2C and 2D). Again TNF-a
treatment showed a mild negative effect on cartilage stain-
ing. Combination with FTY720-P led to discoloration of
the upper half of the cartilage explants. This effect was
independent of whether cartilage explants were placed in
the culture wells correctly or up-side down (Figure 2E and
2F).
FTY720-P mediated GAG depletion is dependent on
functional MMP-3
As MMP-3 is crucial for activation of pro-MMP’s, we used
XG076, an inhibitor of pro-MMP-3 activation. Upon inhi-
bition of pro-MMP-3 with XG076 the effect of IL-1b and
TNF-a on GAG depletion was rendered to levels of the
untreated controls. Furthermore co-treatment with 3 μM
FTY720-P did not result in increased GAG depletion
(Figure 3A).
FTY720-P reduces cytokine-induced MMP-13, but
enhances MMP-3 and ADAMTS-5 expression
To asses which protease was responsible for the enhanced
GAG depletion by FTY720-P we examined gene expres-
sion of MMP-1,-3.-13, ADAMTS-4,-5 and COX-2. Treat-
ment of chondrocytes with either IL-1b or TNF-a led to a
5.5-fold and 8.4-fold up-regulation of MMP-13 mRNA,
respectively (both with P < 0.01). Co-treatment with
FTY720-P reduced MMP-13 mRNA expression by 52 ±
8% and 74 ± 9% (both P < 0.05, Figure 3B)
In contrast to the effect of FTY720-P on MMP-13,
MMP-3 and ADAMTS-5 expression induced by IL-1b
was further enhanced by FTY720-P, however not reaching
statistical significance (P = 0.063 and 0.054 respectively;
Figure 3C and 3D). Expression of COX-2, ADAMTS-4
and MMP-1 was enhanced by TNF-a and IL-1b treat-
ment. No effect was observed upon co-treatment with
FTY720-P (data not shown).
Discussion
Our study examines the impact of the small-molecule
immunosuppressant FTY720 on articular cartilage. We
demonstrate that FTY720-P strongly enhances GAG
degradation in the presence of the inflammatory cyto-
kines IL-1b and TNF-a. This effect may result from
FTY720’s functional antagonism on S1P signaling.
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Figure 1 FTY720-P reduces cytokine-induced iNOS expression.
(A) iNOS mRNA was quantified by real-time PCR after 3 h of
treatment of chondrocytes grown in monolayer with the indicated
concentrations of FTY720-P in combination with 10 ng/ml IL-1b or
100 ng/ml TNF-a. Values were normalized to GAPDH and are
presented as percentage of iNOS expression induced by cytokine
treatment. Data are means ± SEM of 3 independent experiments. *P
< 0.05 versus cytokine treated vehicle control. (B) Representative
Western blot from total protein isolated after 24 h treatment with
10 ng/ml IL-1b or 100 ng/ml TNFa and co-treatment with 3 μMo f
FTY720-P or the appropriate amount of vehicle solution (C) Intensity
of Western blots was quantified by densitometry and is expressed
as a ratio of iNOS versus actin. Data are means ± SEM of 3
independent experiments. *P < 0.05, ** P < 0.01.
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Page 4 of 8FTY720-P leads to internalization of the S1P1 receptor
thereby compromising S1P signaling [6]. S1P however
physiologically protects articular cartilage from IL-1b
induced GAG loss [11]. Interestingly FTY720-P does
not lead to GAG loss in the absence of cytokines, sug-
gesting that either activation of catabolic signaling path-
ways or the occurrence of cartilage damage is required
by FTY720-P to inflict GAG depletion. The latter is sup-
ported by the finding that FTY720-P failed to induce
GAG loss in the presence of inflammatory cytokines
when their degradative effect was blocked by XG076.
One can hypothesize a negative feed-back loop induced
by active MMP’s or degraded GAG involving the S1P1
receptor, in order to confine uncontrolled cartilage
destruction. Internalization of S1P1 by FTY720-P would
block such a pathway resulting in enhanced GAG
destruction by IL-1b and TNF-a.
In order to identify the proteases responsible for the
break-down of GAG, we investigated the impact of
FTY720-P co-treatment on the expression of genes
implicated in GAG metabolism. We did not find a cor-
respondent change of expression in the genes examined.
T h et r e n dt o w a r d si n c r e a s eo fMMP-3 and ADAMTS-5
expression upon co-treatment of FTY720-P with IL-1b
is unlikely to cause the pronounced effect on GAG
metabolism. Therefore other proteases or post-transcrip-
tional mechanisms may be responsible for the enhanced
loss of GAG.
In animal models of rheumatoid arthritis administra-
tion of FTY720 prevented or ameliorated joint inflamma-
tion due to its immunosuppressive properties [9,10,18].
None of these studies investigated cartilage break-down
in detail. The persistence of cartilage damage in spite of
FTY720 treatment was reported in SKG mice [18]. How-
ever, the study design did not allow the assessment of a
possible direct impact of FTY720 on cartilage damage.
Interestingly, FTY720 was not able to alter the course of
collagen-induced arthritis when it was administered after
the disease had developed [19]. In this setting there was a
trend of increased joint damage in mice treated with
FTY720 compared to untreated mice.
Contrary to the effects of FTY720-P on GAG metabo-
lism iNOS and MMP-13 gene expression were significantly
diminished by co-treatment with FTY720-P. This effect
was also observed in the absence of TNFa or IL-1b (data
not shown) and is similar to chondrocytes treated with
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Figure 2 FTY720-P enhances cytokine-induced GAG loss. Cartilage explants were treated as indicated for 8 days. Formalin fixed and paraffin
embedded explants were then stained with safranin O. (A) untreated; (B) 3 μM FTY720-P; (C) 10 ng/ml IL-1b; (D) 10 ng/ml IL-1b and 3 μM
FTY720-P; (E) 100 ng/ml TNF-a; (F) 100 ng/ml TNF-a and 3 μM FTY720-P. The figure shows representative pictures taken from one of 3
independent experiments. (G) GAG depletion was assessed by 1,9-dimethylene blue assay after treatment over 5 days with FTY720-P alone or (H)
in the presence of 10 ng/ml IL-1b and 100 ng/ml TNF-a. Data are means ± SEM of 3 independent experiments. *P < 0.05, ** P < 0.01.
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Page 5 of 8S1P [11]. It may therefore result from the agonistic impact
of FTY720-P on S1P3 receptors [20]. In line with these
findings a previous study reported that S1P diminished IL-
1 induced iNOS expression in renal mesangial cells [21].
In cartilage excess of nitric oxide (NO) produced by iNOS
forces chondrocytes to undergo apoptosis [22,23]. Further-
more, NO inhibits GAG and collagen II synthesis in chon-
drocytes and iNOS knock-out mice exhibit less cartilage
degradation in models of OA and RA than their wild-type
litter mates [24-26]. Reduction of iNOS expression by S1P
and FTY720-P may inhibit excess of NO thereby allowing
normal production of extra-cellular matrix constituents. In
our experimental setting this potentially anabolic effect
could not compensate for the catabolic effect of FTY720-P
on GAG homeostasis.
One limitation of the current study is the use of
bovine chondrocytes. Furthermore part of the data was
obtained from chondrocytes in monolayer culture.
Moreover, it is unknown if concentrations of FTY720-P
used in this study are found in human joints. In an ani-
mal study Matsumoto et al. measured a mean serum
concentration of 0.1 μM FTY720 after oral administra-
tion of 1 mg/kg to rats [27]. Assuming that similar con-
centrations are present in synovial fluid, the
concentrations of FTY720-P used in the current study
would exceed FTY720 levels in rats ten-fold. This how-
ever seems acceptable as FTY720 is phosphorylated
intracellularly and released to act in an auto- and para-
crine manner. Therefore local concentrations of
FTY720-P may well exceed those of systemic FTY720.
Conclusions
Our data indicate that FTY720-P influences the metabo-
lism of chondrocytes in a dichotomous way. As an
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Figure 3 GAG depletion is dependent on MMP-3 activation. (A) GAG depletion was assessed by 1,9-dimethylene blue assay after treatment
for 5 days in the presence of 100 μM XG076. Data are means ± SEM of 3 independent experiments. *P < 0.05, **P < 0.01 vs. corresponding
treatment without inhibitor. (B) MMP-13, (C) MMP-3 and (D) ADAMTS-5 mRNA was quantified by real-time PCR after 3 h of treatment with the
indicated concentrations of FTY720-P in combination with 10 ng/ml IL-1b or 100 ng/ml TNF-a. Values were normalized to GAPDH and are
presented as percentage of gene expression induced by cytokine treatment. Data are means ± SEM of 3 independent experiments. *P < 0.05, **
P < 0.01 versus cytokine treated vehicle control.
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Page 6 of 8agonist of the S1P3 receptor FTY720-P reduces expres-
sion of iNOS and MMP-13, whereas it enhances GAG
destruction probably due to its antagonistic properties
at the S1P1 receptor. Therefore the administration of
FTY720 might enhance loss of cartilage in an inflamma-
tory environment. Especially in pre-existing osteoarthri-
tis and in rheumatoid arthritis with abundant expression
of TNF-a and IL-1b the use of FTY720 may accelerate
cartilage degradation. However, further research is
needed to elucidate the impact of FTY720 on cartilage
in human joint diseases.
Additional material
Additional file 1: Table S1. Primers and protocol of real-time PCR.
Additional file 2: Table S2. Minimum information for publication of
quantitative real-time PCR experiments.
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